Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC Meeting Abstract
| Authors: | Deininger, M.; Apperley, J.; Arthur, C. K.; Chuah, C.; Hochhaus, A.; de Lavallade, H.; Lipton, J. H.; Lomaia, E.; McCloskey, J. K.; Maness, L. J.; Mauro, M. J.; Moiraghi, B.; Pavlovsky, C.; Rosti, G.; Rousselot, P.; Sutton, M. U.; Ren, X. W.; Vorog, A.; Kantarjian, H. M.; Cortes, J. E. |
| Abstract Title: | Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557401571 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.6501 |
| Notes: | Meeting Abstract: 6501 -- Source: Wos |
